Mason Freeman, M.D. joined 5AM Ventures as a Scientific Advisor in 2007 and became a Venture Partner in 2008. He serves as Chief of the Lipid Metabolism Unit and Director of the Massachusetts General Hospital’s (MGH) Translational Research Center. Dr. Freeman currently is a Director of Crinetics Pharmaceuticals and previously served as Clinical Advisor to Relypsa and a Director for Envoy (acquired by Takeda). Trained in internal medicine and endocrinology, Dr. Freeman has spent twenty-five years studying the trafficking of lipids in and out of cells via receptors and transmembrane transporters. Following post-doctoral research fellowships in the Biology Department at MIT and the Endocrine Division at MGH, he became Chief of the MGH’s Lipid Metabolism Unit in 1992. At MGH, he oversees a new academic clinical drug development center, the hospital’s lipid disorders clinic and a basic science research program focused on atherosclerosis. From 2005 to 2007 he led the Novartis Translational Medicine Program for Cardiovascular & Metabolic Diseases and was Global Head of Biomarker Development. At Novartis and 5AM, he contributed to the development of ENTRESTO for heart failure and VELTASSA for hyperkalemia. Dr. Freeman is a Professor of Medicine at Harvard Medical School. He received his B.A. from Harvard College and his M.D. from the University of California, San Francisco. Dr. Freeman is based in the Boston, MA office.
Copyright © 2017 5AM Venture Management LLC